Our findings suggest that targeting the HK3/EP300/TFAP2A axis could be a potential therapeutic strategy to enhance the efficacy of PD-L1-mediated immune checkpoint blockade therapy for ccRCC patients. Here, EP300 is linked to nonpapillary renal cell carcinoma.